Gout

A review of 15 RCTS suggests that both electroacupuncture and conventional drugs demonstrate similar effectiveness in addressing pain for patients with acute gouty arthritis.

Gout incidence rate significantly increased after relieving urinary tract obstruction.

Mortality risks in gout have not improved in the United States in the past 3 decades, with a similar risk found among contemporary cases of gout in the United Kingdom.

There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.

Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.

Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.

Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.

Patients with gout who did not experience recurrent flares had a shorter mean time between diagnosis and the start of urate-lowering therapy compared with those who had ≥1 flare.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

This analysis resulted in several valuable insights related to the landscape of gout patients’ changes in their blood immune cells between flares and periods of remission.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

This new data expanded upon research into gout’s molecular pathogenesis and into ULT for managing non-gout diseases such as hyperuricemia.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.

A virtual screening combined with experimental verification identified the potential mechanism of fuzitang decoction in the treatment of Gouty Arthritis.

Nonsteroidal anti-inflammatory drug use and prednisolone equivalent dose >5 mg per day were associated with an increased risk of NAFLD, whereas hydroxychloroquine use and prednisolone equivalent dose ≤5 mg per day were associated with a decreased risk of NAFLD.

SIRI emerged as a significant factor influencing acute gout attacks, shedding light on a prospective diagnostic tool.

John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.

In this research presented at ACR 2023, investigators looked at potential factors which could predict flare risk after urate-lowering therapy initiation.

The 2 groups—the active control group who received smartphone notifications about general health advice and the intervention group who receive notifications on adherence-targeted information—did not have significant differences in serum urate levels.

In a recent study, participants had highest gout flare rates when serum urate levels were > 10 mg/dL and the lowest gout flare when levels were < 3.9 mg/dL.

Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.

This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.

Receipt of RZV was not associated with an increased risk of incident gout among more than 1,000 adults ≥ 65 years of age who received at least 1 dose of the 2-dose vaccine regimen.

At the follow-up with a study sample of 16.7 million patients, 6.9% of gout patients had chronic opioid use (n = 28,948) while 3.8% of the non-gout patients did.

Lifestyle habits including vegetable consumption and exercise were associated with Gout Impact Scale score.